Impact of weight loss after treatment on survival outcomes of overweight and obese patients with early‑stage endometrial cancer.

death endometrial cancer obesity overweight recurrence weight loss

Journal

Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236

Informations de publication

Date de publication:
Feb 2024
Historique:
received: 02 06 2023
accepted: 05 09 2023
medline: 18 12 2023
pubmed: 18 12 2023
entrez: 18 12 2023
Statut: epublish

Résumé

Despite the fact that obesity is the main risk factor for endometrial cancer, there is limited evidence regarding the effects of body weight change on overweight and obese women treated for early-stage endometrial can its impact on cancer outcomes. A retrospective cohort study was performed including all overweight and obese patients with early-stage type-I endometrial cancer that were treated at the Insular University Hospital of Las Palmas (Las Palmas de Gran Canaria, Spain) between January 2007 and December 2019. Body weight change at 12 months of treatment was evaluated, as well as its impact on cancer outcomes. Weight loss ≥5% was independently evaluated regarding its impact on survival. A total of 526 women were studied, of which 152 (28.90%) were overweight (BMI ≥25 and <30) and 374 (71.10%) were obese (BMI ≥30). The median follow-up was 76.17 months, during which time 77 (14.64%) women died. In the survivor group, body weight at initial diagnosis was 86.4±17.9 kg compared with 84.6±16.4 kg 1 year after treatment, which corresponded to a significant mean weight loss of 1.47 kg (P<0.001). However, in the group of non-survivors, body weight at initial diagnosis was 84.7±15.7 kg compared with 84.7±14.6 kg 1 year after treatment, which demonstrated a non-significant mean weight loss of 0.63 kg (P=0.180). When comparing between the patients who maintained or gained ≥5% weight and those who lost ≥5% weight, there were no significant differences taking into account the whole cohort and follow-up time; however, when adjusting for the period between 32 and 98 months, survival was significantly higher in those patients that lost ≥5% of their initial body weight (P=0.025; log-rank test). Based on the final univariate and cer and multivariate analyses, body weight change at 12 months was not indicated to be a factor significantly affecting overall survival; adjusted hazard ratio was 1.01 (95% CI 0.97-1.05, P=0.723). In conclusion, even if greater weight loss is observed in patients with endometrial cancer that survive the disease, no significant impact on survival outcomes is observed based on multivariate analysis.

Identifiants

pubmed: 38106524
doi: 10.3892/ol.2023.14177
pii: OL-27-2-14177
pmc: PMC10722546
doi:

Types de publication

Journal Article

Langues

eng

Pagination

44

Informations de copyright

Copyright © 2023, Spandidos Publications.

Déclaration de conflit d'intérêts

The authors declare that they have no competing interests.

Auteurs

Beatriz Navarro Santana (BN)

Doctoral School, University of Las Palmas de Gran Canaria, 35001 Las Palmas de Gran Canaria, Spain.
Department of Gynecologic Oncology, Insular University Hospital of Las Palmas, 35016 Las Palmas de Gran Canaria, Spain.

Jose Verdú Soriano (JV)

Department of Community Nursing, Preventive Medicine, Public Health and History of Science, Faculty of Health Sciences, University of Alicante, 03690 Alicante, Spain.

Octavio Arencibia (O)

Department of Gynecologic Oncology, Insular University Hospital of Las Palmas, 35016 Las Palmas de Gran Canaria, Spain.

Stamatios Petousis (S)

2nd Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.

Chrysoula Margioula-Siarkou (C)

2nd Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.

Daniel González (D)

Department of Gynecologic Oncology, Insular University Hospital of Las Palmas, 35016 Las Palmas de Gran Canaria, Spain.

Maria Laseca (M)

Department of Gynecologic Oncology, Insular University Hospital of Las Palmas, 35016 Las Palmas de Gran Canaria, Spain.

Andrés Rave (A)

Department of Gynecologic Oncology, Insular University Hospital of Las Palmas, 35016 Las Palmas de Gran Canaria, Spain.

Alicia Martín Martínez (AM)

Department of Gynecologic Oncology, Insular University Hospital of Las Palmas, 35016 Las Palmas de Gran Canaria, Spain.

Classifications MeSH